Piper Sandler analyst Do Kim made no change to the firm’s Overweight rating or $104 price target on Gilead shares after the FDA approved Sunlenca for heavily treatment-experienced HIV ahead of the December 27 PDUFA date. The analyst expects strong Sunlenca uptake, and expects that expansion into the broader HIV market, including prevention, will provide a better sense of patient demand for an injectable with less frequent dosing than standard oral therapies, Kim tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Gilead announces Sunlenca granted FDA approval in multidrug resistant HIV
- Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c
- Kite to acquire Tmunity, terms undisclosed
- Gilead, Arcus announce results from fourth interim analysis of ARC-7 study
- GILD vs. AMGN: Two Splendid Dividend Stocks, but One Looks Better